Africa Shifts Focus to Treatments

ANTICOV, Africa’s largest COVID-19 clinical treatments trial, is now underway and recruiting participants in more than a dozen countries from Cameroon to Sudan.
First up: A study of the combo of antiparasitic nitazoxanide and inhaled corticosteroid ciclesonide—both commercially available and affordable—which could potentially hamper the virus’s replication in the body and decrease upper respiratory tract inflammation.
A key goal: Preventing mild-to-moderate cases from progressing into severe illness—and overwhelming health systems with limited resources. 

The Quote: “What might be considered a small number of severe diseases in the global north might have devastating consequences in Africa,” says Borna Nyaoke-Anoke, a DNDi clinical manager heading up the ANTICOV trial in Nairobi.

Why treatment options are urgent:  Limited vaccines for African countries. Kenya, for example, only expects to have enough vaccines to cover 30% of its population by June 2023.

Comments +


Post a Comment

Restricted HTML

  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Back to top